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Abstract
National surveillance of Legionnaires’ disease (LD) is important to inform control measures and facilitate international networking for timely
reporting. This study is the ﬁrst to describe the molecular epidemiology of LD in Israel. Case notiﬁcations for 2006–2011, collated through
mandatory reporting, were identiﬁed and demographic, clinical and laboratory data were extracted. Unrelated clinical and environmental
Legionella pneumophila strains were characterized using standard procedures, Dresden panel of monoclonal antibodies and the ESCMID
Study Group for Legionella Infections (ESGLI) Sequence-Based Typing scheme. In all, 294 cases were reported (crude incidence 0.67 cases/
100 000; age-standardized incidence 1/100 000). LD epidemiological trends and features largely resembled those of the EU, except for a
larger proportion of nosocomial cases. Of 28 clinical and 23 environmental strains analysed, 71.4% and 21.7% were serogroup (sg) 1 and the
most common immunological subgroup was OLDA/Oxford (64%). Of the clinical strains, OLDA/Oxford, ST1 was the most common (43%)
followed by Allentown/France, ST40 (14%). The unusual sg 3 ST338 was found in 17.4% of environmental strains. Novel STs were detected
amongst 23.5% of strains. These ﬁndings warrant further molecular investigation. Molecular epidemiology data generated from neighbouring
countries newly adopting the ESGLI typing scheme for L. pneumophila contribute to understanding of regional strain diversity.
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Background
Legionellae are Gram-negative bacteria ubiquitously found in
aqueous environments [1]. Humans can be infected through
exposure to aerosol particles generated from contaminated
man-made water systems, such as spa pools, cooling towers or
showering facilities. Clinical manifestation varies from a mild
inﬂuenza-like illness called Pontiac fever to pneumonia of
varying severity known as Legionnaires’ disease (LD) [2].
Amongst the 60 or more Legionella species, Legionella pneumo-
phila causes the vast majority of LD and out of 16 known
serogroups, L. pneumophila serogroup 1 accounts for over 80%
of LD cases [3,4].
Legionnaires’ disease is a reportable communicable disease
in many European countries, with an overall incidence of 1.16
per 100 000 EU population [4]. EU surveillance of LD is
coordinated by the European Legionnaires’ Disease Surveil-
lance Network (ELDSNet) of the European Centre for Disease
Prevention and Control (ECDC). Surveillance data demon-
strated a mild increase in the incidence of legionellosis over
the last decade and excess morbidity in recent years that may
be associated with climate change [5,6].
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The standardized sequence-based typing (SBT) scheme for
L. pneumophila developed by the European Working Group
for Legionella Infections (EWGLI, now European Society for
Clinical Microbiology Study Group on Legionella Infections,
ESGLI) marked an important advancement in the study of the
molecular epidemiology of LD [7,8]. Implementation of SBT
has yielded useful and comparable data at a regional, national
and international level [9] and has also been shown to have an
important role in the investigation of unusual LD cases [10]
and LD outbreaks [11].
Currently, there are only limited data on the epidemiology
of LD in Israel and no molecular epidemiology data. The aim of
this report is to present national surveillance data from Israel
collated in recent years and results of molecular typing
following the implementation of SBT in this country.
Methods
The study was conducted by the Israeli Ministry of Health. LD
is a reportable disease in Israel and LD case data are passively
reported to the MOH Division of Epidemiology by District
Health Ofﬁces following reports generated by frontline
clinicians. A case of LD was deﬁned as an acute respiratory
illness with laboratory evidence of infection with L. pneumo-
phila by urinary antigen testing, serology, sputum culture or
molecular detection in sputum by PCR based on modiﬁcation
of EU case deﬁnition [12]. All cases of LD reported to the
MOH between 2006 and 2011 were identiﬁed in the registry
of notiﬁable diseases and relevant available data were
extracted and analysed, including demographic data, underlying
risk factors, setting of exposure, laboratory diagnosis and
outcome.
A convenience sample of L. pneumophila strains recovered
during the study period was chosen from the MOH strain
repository. Clinical strains were recovered from respiratory
samples of suspected LD patients and identiﬁed by standard
laboratory procedures at the point of care, prior to referral to
the reference laboratory. Environmental strains were recov-
ered at MOH-certiﬁed public health laboratories from inspec-
tion samples obtained from water systems according to
national regulations. Clinical and environmental strains were
epidemiologically unrelated.
Isolates were cultured on BCYEa plates (Oxoid, Basing-
stoke, UK) for 48–72 h at 35°C before phenotypic and
molecular tests were performed. Presumptive identiﬁcation as
L. pneumophila was conﬁrmed using the MonoFluo Legionella
pneumophila IFA Test (Biorad, Hemel Hempstead, UK), then
the Dresden panel of monoclonal antibodies was used to
determine the serogroup and, in the case of sg 1 strains, the
subgroup [13]. Strains not readily conﬁrmed as L. pneumophila
were identiﬁed to species level by sequencing the mip gene as
described by Ratcliff et al. [14] and comparing the sequence to
the mip database [15].
Between two to three single colonies per L. pneumophila
strain were pelleted and DNA extracted using the InstaGene
Matrix (Biorad). The genotype of each strain was determined
using the M13 modiﬁcation of the ESGLI SBT method [16]. All
alleles and sequence types (STs) were determined using the
Legionella Sequence Quality Tool [17,18].The global frequency
of speciﬁc sequence types for comparison with local ﬁndings
was obtained from SBT database queries as of 1 July 2013. The
strain diversity index was calculated according to the modiﬁed
method of Hunter and Gaston [19].
Results
Demographic data
During the study period, 294 cases of LD were reported; an
annual mean of 49.3 cases (range 38–63 cases per year). These
frequencies corresponded to an annual incidence rate of 0.5–
0.9 cases per 100 000 population (mean incidence 0.67 per
100 000). The mean age was 62.2  19.2 years (median 65.5,
range 2 months to 99 years). The vast majority of cases
(86.4%) occurred amongst patients over 45 years of age, and
51.7% of cases occurred amongst the 65+ year age band. The
age-speciﬁc mean annual incidence rates in the 45–64 year and
65+ year age bands were 1.2 and 3.5 per 100 000 population,
respectively. Male patients accounted for 201 LD cases
(68.3%), yielding a male-to-female ratio of 2.16:1.
Seasonal distribution of LD cases showed a slightly
increased occurrence during the warm season, with 51% of
cases diagnosed between July and November (Fig. 1). The main
geographical areas from which LD cases were reported
included northern Israel (132 cases, 49%), central Israel (80
cases, 27.2%) and the Tel-Aviv region (71 cases, 24.15%). Only
a few cases were reported from Jerusalem and the southern
districts. The adjusted incidence per district was highest in the
Haifa district of northern Israel (1.5/100 000), followed by the
Tel-Aviv and central districts (0.9 and 0.8/100 000, respec-
tively).
Clinical features
The setting of exposure was known in 156 cases (53%), of
which 45.5% were healthcare-associated acquisitions (24%
overall), followed by community acquisitions in 39.6% (21%
overall) and travel-associated acquisitions (TALD) in 15% (8%
overall). Apart from male sex and age, the most common risk
factors for LD found amongst patients were chronic renal
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failure (19%), malignancy (19%), diabetes mellitus (16%),
immune system compromise (7%), including bone marrow
transplantation, solid organ transplantation, corticosteroid
therapy and HIV, and chronic respiratory disease (4%). LD
was diagnosed by urinary antigen test in 88% of patients,
culture in 7%, serology in 3% and PCR in 2%. The case fatality
rate was 12.6%.
Phenotypic and molecular subtyping
In all, 28 clinical strains and 23 environmental strains were
characterized at both phenotypical and molecular level.
Serogrouping results are summarized in Table 1. The majority
of clinical strains (71.4%) were sg 1, whereas for environmental
strains, sg 3 was most prevalent (52.2%). The distribution of
subgroups amongst sg 1 strains is depicted in Table 1. Notably,
FIG. 1. Seasonal distribution of Legionnaires’ disease cases, 2006–2011.
TABLE 1. Clinical and environmental Legionella pneumophila strains by serogroup and subtype
Source Serogroup N (%)
Monoclonal
subgroup
N (% of sg.1
strain)
Sequence
type
N (% of clinical
strains)
Healthcare-
associated
cases
Global
frequency of
STa
N %
Clinical (N = 28) 1 20 (71.4) OLDA/Oxford 11 (64) ST1 12 (42.85)d 1 983 13.3
Allentown/France 4 (16) ST23 1 (3.6) 542 7.34
ST40 4e (14.3) 1 99 1.34
ST1207b 1 (3.6) NAf
Benidorm 1 (4) ST1206b 1 (3.6) 1 NA
Knoxville 1 (4) ST345 1 (3.6) 12 0.16
Not tested 3 (12) NA NA NA NA
3 4 (14.3) NA ST87 2 (7.15) 45 0.6
ST338 1 (3.6) 1 11 0.15
ST93 1 (3.6) 51 0.69
4 2 (7.1) Untypeablec 2 (7.15) 1 NA
6 1 (3.6) ST1208b 1 (3.6) NA
8 1 (3.6) ST1351b 1 (3.6) NA
Environmental
(N = 23)
1 5 (21.7) OLDA/Oxford 5 (100) ST1 5 NA 983 13.3
3 12 (52.2) NA ST87 1 45 0.6
ST338 4 11 0.15
ST464 1 3 <0.1
ST949 1 1 <0.1
ST1269b 1 NA
ST1271b 4 NA
6 6 (26.1) ST187 2 24 0.32
ST461 1 2 <0.1
ST1208b 1 NA
ST1270b 2 NA
aAs of 15 July 2013; combined clinical and environmental strains.
bNovel ST.
cOnly a partial allelic proﬁle has been generated due to failed ampliﬁcation of certain loci.
dOne isolate was not mAb typed.
eTwo isolates were not mAb typed.
fNot applicable.
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OLDA/Oxford was the most common subgroup, accounting
for 64% of sg 1 strains (55% of sg 1 clinical strains and 100% of
sg 1 environmental strains).
The frequency of the obtained sequence types (STs)
according to SBT results is summarized in Table 1. The most
common was ST1 (accounting for 33.3% of strains, roughly half
of clinical and a quarter of environmental strains) and all 17
ST1 strains belonged to the OLDA/Oxford Dresden subgroup.
L. pneumophila sg 1 OLDA/Oxford ST1 is thus the leading
strain found in LD in Israel. This phenon accounts for 39% of
ST1s in the global Legionella database. Of clinical strains, the
second most common was ST40, which accounted for 14.3%
of strains in Israel but is relatively uncommon globally. All
these strains belonged to the ‘Allentown/France’ subgroup of
sg 1, which is the typical phenon found in ST40. Of
environmental strains, the second most common ST was
ST338 (17.4%), an sg 3 previously reported only on rare
instances.
Interestingly, 12 (23.5%) of the L. pneumophila strains
yielded novel STs. Most of those strains were sg 3 (ST1269,
ST1271) or sg 6 (ST1208, ST1270, ST1438) and the remainder
were sg 1 (ST1206, ST1207) or sg 8 (ST1351). The calculated
diversity index was 0.775 for clinical isolates and 0.909 for
environmental isolates. The diversity of study strains is shown
in Fig. 2.
Discussion
Until recently, data on LD in Israel have been limited to case
reports or case series [10,20] as well as prevalence data based
on serological testing for legionella amongst a large cohort of
patients with respiratory infections in southern Israel, showing
rates of up to 16.2% [21,22]. The increasing volume of activity
following the revision of national regulations for legionella
control in water systems in Israel over recent years, the
challenges associated with linking LD cases to environmental
sources and the growing need to enhance international
collaboration with regard to travel-associated LD have played
a key role in the inauguration of a National Programme for
Legionellosis Control in Israel. This study, which is the ﬁrst to
outline the molecular epidemiology of LD in Israel, reﬂects the
priorities set by the programme.
The annual incidence of LD found in Israel is slightly lower
than that reported on average in Europe [4]. Taking into
account Israel’s warm climate that renders ‘cold’ water
systems ‘hot’ for most of the year, we hypothesized that LD
incidence would be relatively high. Observed rates of notiﬁ-
cations could be explained by under-diagnosis, under-report-
ing, efﬁciency of control measures, differences in distribution
of age and host risk factors in the Israeli population or a
combination of such factors. That almost no cases of LD were
reported from certain geographical regions, such as the south
of Israel, which has the warmest climate, strongly suggests that
under-diagnosis may have indeed occurred. This is plausible,
especially because the seasonal distribution of LD in Israel
resembles that of the EU, with the exception of the proportion
of cases occurring in November.
Notably, the age distribution and sex ratio of LD in Israel
were strikingly similar to those reported from the EU [5]. In
order to account for differences in population composition
and age as a risk factor, incidence rates of Israel were subject
to standardization by the direct method taking the average EU
population as standard [23]. The age-standardized incidence
rates increased from a range of 0.5–0.9 per 100 000 to 0.8–1.3
per 100 000 and the mean annual incidence increased
following standardization from 0.67 to 1 per 100 000 popu-
lation, which is very close to the EU average.
The setting of exposure observed in Israel markedly differs
from that of the EU [5]. The proportion of nosocomial LD
(24%) is much higher than in the EU (5%) whereas the
proportion of combined domestic and international TALD
FIG. 2. Minimum spanning tree showing the distribution of clinical
(red) and environmental (blue) Legionella pneumophila strains with
seven sequenced alleles in relation to sequence type (ST). ST number is
shown and circle size indicates the number of strains assigned to ST.
Thick lines connect single-locus variants, thin lines connect dou-
ble-locus variants and dotted lines connect other variants (more than
two allele difference).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 690–696
CMI Moran-Gilad et al. Molecular epidemiology of Legionnaires’ disease 693
(8%) is much lower (24%). Possible explanations for that
observation include the lack of historical data for 47% of cases
and suboptimal TALD surveillance before 2012. Speciﬁcally, it
is possible that nosocomial cases are more likely to be
diagnosed and reported and thus our ﬁndings represent a
surveillance bias. As a result, these factors have been rectiﬁed
in order to ensure adequate data for future surveillance.
It is noteworthy that none of the reported LD cases in Israel
were associated with disease clusters whereas in the EU 7% of
cases with known status are related to clusters [5]. Because all
cases of LD in Israel are investigated by local health authorities
we believe that under-diagnosis does not explain lack of
clusters. Even in Europe, no clusters were noted in 16 out of
27 countries, and most clusters were reported from as few as
four countries. This suggests differences in epidemiology and
surveillance between countries. In Israel, only a few LD
clusters have been reported over the last two decades. These
include a nosocomial outbreak involving a bone marrow
transplant unit [24] and a well publicized cluster involving a
hotel in Eilat (http://www.q-net.net.au/~legion/legionnaires.
disease.2003.html). Whether this is associated with enforce-
ment of control measures or virulence of circulating strains
remains to be determined.
The case fatality rate observed in our cohort is slightly higher
than that reported from the EU (12.6% vs. 9%). This may reﬂect
the larger proportion of nosocomial cases in our cohort, which
may involve patients at high risk of mortality due to their
underlying health conditions, such as immunocompromised
patients, who comprised over a quarter of our patient sample.
Reliance on urinary antigen testing for LD diagnosis was
evident in our patient series as reported from most countries,
for example Italy [25]. In 2011, 77%, 12% and 4% of EU patients
were diagnosed by means of urinary antigen, culture and PCR,
respectively [5]. The use of such tests in Israeli hospitals was
similar and in light of the increasing availability of frontline
molecular diagnostics, the fraction of PCR-positive cases is
expected to be higher in the forthcoming years. This approach
may be expected to increase the detection of LD cases caused
by non-sg. 1 strains, which may be overlooked by urinary
antigen testing.
Our molecular analysis revealed 19 distinct STs found
amongst the 51 characterized strains obtained over a 6-year
period. This corresponded to an index of diversity of 0.775
and 0.909 for clinical and environmental strains, respectively.
Other nationwide studies have yielded 86 STs amongst 214
isolates in Canada over a 29-year period [26] or 53 STs
amongst 86 isolates in Japan over a 28-year period [27]. Both
studies found an index of diversity >0.9 for clinical strains.
Similarly high diversity indices were also found in the United
Kingdom [9]. One probable explanation for the relatively low
level of diversity found in our clinical strain series is the
abundance of ST1, which accounted for over 40% of strains.
Whilst the number of study years and country size may
negatively contribute to strain diversity, the high index of
diversity found in our environmental strain collection suggests
that these factors cannot solely account for such ﬁndings.
ST1 has been shown to be the most common strain in many
countries [28,29] and is commonly found in the environment
even when the number of ST1-associated LD cases is low [9].
ST1 has also been reported as the most common ST causing
infection in Germany in a study that included a large
proportion (45.7%) of nosocomial cases [30]. In our molecular
analysis, only ﬁve clinical strains (18%) were of nosocomial
origin and thus it is difﬁcult to draw conclusions on the role of
ST1 as a cause of nosocomial LD in Israel. While one of those
involved ‘OLDA/Oxford, ST1’, this should be addressed in
future studies. Notably, ST1 is found more commonly in
man-made as opposed to natural water sources [26]. Mindful
of the arid conditions found in many parts of Israel, STs typical
of natural water sources are less likely to be encountered, thus
increasing the proportion of ST1.
ST47 is very common in many EU countries, such as the
United Kingdom [9], Belgium [31], France [32] and the
Netherlands [33]. No ST47 strain was found in our study, either
in the environment or in clinical samples.We cannot rule out the
possibility that ST47 was not detected due to the small sample
size and therefore, the presence of this important strain should
be assessed prospectively. In addition to ST1 and ST47, several
other types are relatively common from a global perspective.
These include in decreasing order of frequency ST23, ST62,
ST42, ST9 and ST37. Together with ST47, these types account
for 21% of SBT database entries. Except for one ST23 strain,
none of those have been detected in our study and this further
emphasizes the unique ST distribution found in Israel.
Our study has several limitations, including the limited
number of years and relatively small sample size of studied
strains. Moreover, due to under-diagnosis and under-reporting
as well as missing meta-data, our data could have been biased
towards inclusion of nosocomial LD and thus may not
adequately reﬂect community-acquired LD.
Conclusions
This is the ﬁrst study on the molecular epidemiology of LD in
Israel. Our data demonstrate many similarities to the epide-
miological trends found in EU countries, especially in relation
to incidence rates, seasonality and methods used for labora-
tory diagnosis. Notably, our data include a larger proportion of
nosocomial cases than that reported in many countries.
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The molecular characterization of our L. pneumophila
strains shows several unusual features, including an unusually
high percentage of the sg 1 ‘OLDA/Oxford, ST1’ phenon
leading to reduced clinical strain diversity, a notable number of
clinical cases involving the sg 1 ‘Allentown/France, ST40’
phenon and the presence of the rare sg 3 ST338 strain in the
environment. In addition, a substantial percentage of our
strains yielded novel STs, which were added to the global
Legionella SBT database.
Accumulation of molecular epidemiology data from neigh-
bouring countries newly adopting the ESGLI SBT scheme for
L. pneumophila contributes to understanding of regional strain
diversity and may facilitate international activities such as
TALD surveillance. Our ﬁndings deserve further molecular
investigation by expanding the clinical and environmental strain
sample as well as harnessing of genomic technologies to dissect
the molecular epidemiology of ST1, which appears to be the
dominant L. pneumophila strain in Israel.
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